Advicenne

ALDVI · PA · Healthcare / Biotechnology

0.656EUR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.656

Open0.656

Day Range0.656 – 0.675

52-Week Range0.66 – 2.35

Volume7.28K

Market Cap10.44M

P/E (TTM)9.79

Forward P/E0.00

EPS0.07

Dividend Yield0.00%

Beta0.90

50-Day Avg1.27

200-Day Avg1.47

About

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Laurent Cassedanne
Employees11
Headquarters262 Rue du Faubourg Saint-Honore, Paris, France, 75008, France
Websitehttps://www.advicenne.com

Leadership

Mr. Didier LaurensGeneral Director & Chairman of the Board · b. 1966
Mr. Laurent CassedanneDeputy CEO, Deputy GM & Head Pharmacist and Director · b. 1968
Ms. Isabelle KervellaChief Financial Officer
Dr. André Ulmann M.D., Ph.D.Chief Medical Officer, Non-Voting Director & Director · b. 1949
Ms. Hege HellstromChief Commercial Officer · b. 1965
Mr. Robbie McCarthyGeneral Manager of Advicenne Inc.

Financials

Income Statement

Currency: EUR	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	1.85M	109.00K	268.00K	806.30K	1.19M	2.00M	2.06M	2.69M	2.40M	4.46M	4.97M	6.01M
Growth (%)	-	-94.10%	+145.87%	+200.86%	+47.58%	+68.00%	+3.14%	+30.41%	-10.86%	+85.98%	+11.55%	+20.77%
Cost of Revenue	2.28M	44.00K	99.00K	4.45M	8.46M	12.85M	886.00K	973.00K	1.12M	6.68M	6.15M	6.93M
Gross Profit	-433.19K	65.00K	169.00K	-3.65M	-7.27M	-10.85M	1.18M	1.72M	1.28M	-6.31M	-1.18M	-922.00K
Gross Margin	-23.44%	59.63%	63.06%	-452.39%	-610.76%	-542.73%	57.03%	63.82%	53.40%	-141.50%	-23.65%	-15.35%
Operating Expense	2.06M	3.51M	3.34M	1.80M	-1.64M	3.78M	15.31M	14.16M	11.34M	149.00K	7.88M	7.43M
Operating Income	-2.50M	-3.44M	-3.17M	-5.44M	-5.63M	-14.63M	-14.13M	-12.44M	-10.06M	-6.46M	-9.06M	-8.36M
Operating Margin	-135.03%	-3160.55%	-1182.09%	-675.22%	-473.07%	-731.65%	-685.50%	-462.74%	-419.65%	-144.84%	-182.16%	-139.14%
EBITDA	-1.77M	-3.79M	-3.55M	-5.05M	-4.97M	-14.01M	-14.05M	-12.04M	-9.87M	-6.24M	1.30M	-7.81M
EBITDA Margin	-95.67%	-3478.90%	-1324.07%	-626.23%	-417.41%	-700.70%	-681.23%	-447.60%	-411.81%	-140.06%	26.14%	-129.97%
Net Income	-1.99M	-3.77M	-3.98M	-4.65M	-4.63M	-14.20M	-14.85M	-12.43M	-11.47M	-7.03M	-6.46M	-9.53M
Net Income Margin	-107.72%	-3459.63%	-1485.07%	-577.29%	-388.68%	-710.20%	-719.98%	-462.14%	-478.56%	-157.72%	-129.98%	-158.71%
R&D	-	80.00K	80.00K	4.96M	7.13M	7.64M	8.15M	8.96M	7.08M	3.75M	3.00M	3.74M
R&D as % of Total Revenue	-	73.39%	29.85%	614.53%	599.35%	382.21%	395.05%	333.36%	295.24%	84.16%	60.27%	62.29%
Interest Expense	-	164.00K	406.00K	69.16K	10.42K	6.18K	666.00K	1.25M	1.37M	577.00K	1.28M	1.54M
Interest Expense % of Total Revenue	-	150.46%	151.49%	8.58%	0.88%	0.31%	32.30%	46.41%	57.28%	12.94%	25.80%	25.62%

Balance Sheet

Currency: EUR	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	3.22M	2.98M	3.26M	38.62M	33.17M	22.92M	24.00M	18.88M	14.26M	12.41M	9.51M	7.14M
Total Liabilities	1.41M	4.65M	8.41M	5.11M	3.54M	6.00M	20.73M	18.57M	24.88M	24.38M	28.58M	33.51M
Total Equity	1.81M	-1.67M	-5.15M	33.51M	29.63M	16.92M	3.27M	309.00K	-10.50M	-11.97M	-19.07M	-26.37M
Cash	1.50M	1.64M	1.58M	36.18M	26.23M	14.40M	16.77M	12.69M	8.32M	5.25M	3.25M	1.34M
Total Debt	269.00K	3.40M	3.32M	701.68K	419.91K	1.45M	13.80M	12.54M	18.75M	18.32M	18.19M	19.00M
Net Debt	-1.23M	1.76M	1.73M	-35.48M	-25.81M	-13.96M	-2.97M	-147.00K	10.43M	13.07M	14.94M	17.66M

Cash Flow

Currency: EUR	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-	-2.69M	67.00K	-5.80M	-10.18M	-9.47M	-11.69M	-12.53M	-9.15M	-5.99M	-762.00K	-3.73M
Investing Cash Flow	-	-164.00K	-24.00K	-338.00K	-342.00K	-1.11M	-694.00K	-395.00K	-2.00K	-1.32M	-108.00K	-403.00K
Financing Cash Flow	-	3.00M	-95.00K	40.74M	571.00K	983.00K	12.53M	8.85M	4.78M	4.23M	-1.13M	2.23M
Capital Expenditure	0	164.00K	24.00K	35.00K	142.00K	934.00K	575.00K	297.00K	115.00K	1.28M	91.00K	382.00K
Free Cash Flow	-	-2.86M	43.00K	-5.84M	-10.32M	-10.41M	-12.27M	-12.82M	-9.26M	-7.27M	-853.00K	-4.11M
Dividends Paid	-	-	-	-	-	43.00K	41.00K	56.00K	5.00M	-	-	-
FCF to OCF	-	106.09%	64.18%	100.60%	101.39%	109.86%	104.92%	102.37%	101.26%	121.41%	111.94%	110.25%
Dividend Paid to FCF	-	-	-	-	-	-0.41%	-0.33%	-0.44%	-53.98%	-	-	-

Earnings

Report Date	Aug 4, 2016	Feb 3, 2017	Nov 22, 2017	Apr 10, 2018	Sep 20, 2018	May 2, 2019	Oct 1, 2019	Mar 13, 2020	Sep 25, 2020	Apr 28, 2021	Sep 29, 2021	Mar 31, 2022	Sep 21, 2022	Mar 30, 2023	Sep 18, 2024	Apr 29, 2025	Sep 20, 2025
EPS Estimate	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	0.00	0.00	0.00
EPS Actual	-0.29	-0.27	-0.37	-0.39	-0.47	-0.16	-0.85	-0.89	-0.92	-0.84	-0.93	-1.34	-0.48	-1.16	-0.45	-0.36	-0.40
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	Pre-market	After-hours	After-hours	-	-	Pre-market	Pre-market	After-hours	Pre-market	After-hours	After-hours	After-hours	-	-	-

Key Statistics & Ratios

Market Cap10.44M

Enterprise Value30.65M

Trailing P/E9.79

Forward P/E0.00

Price / Sales1.61

Price / Book131.47

EPS0.07

Book Value-1.81

Revenue (TTM)6.50M

Gross Profit (TTM)-1.02M

EBITDA197.00K

Profit Margin0.66%

Operating Margin182.39%

Return on Equity-10277.78%

Return on Assets11.13%

Shares Outstanding15.24M

Shares Float8.88M

Beta0.90

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Jul 2, 2025514:513
Sep 13, 20231049:1030